Page last updated: 2024-10-23

benphothiamine and Diabetes Mellitus, Adult-Onset

benphothiamine has been researched along with Diabetes Mellitus, Adult-Onset in 14 studies

benfotiamine : A thioester that is a synthetic analogue of thiamine obtained by acylative cleavage of the thiazole ring and O-phospohorylation.

Research Excerpts

ExcerptRelevanceReference
" Currently, there are only few pathogenetically oriented pharmacotherapies for DSPN, one of which is benfotiamine, a prodrug of thiamine with a high bioavailability and favourable safety profile."3.11BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy. ( Al-Hasani, H; Bönhof, GJ; Herder, C; Icks, A; Knebel, B; Kuss, O; Reule, C; Roden, M; Sipola, G; Strassburger, K; Strom, A; Wollmann, JC; Ziegler, D, 2022)
"In people with Type 2 diabetes and markedly impaired fasting flow-mediated dilatation, a mixed test meal does not further deteriorate flow-mediated dilatation or variables of microvascular or autonomic nervous function."2.78A randomized, double-blind, crossover, placebo-controlled trial of 6 weeks benfotiamine treatment on postprandial vascular function and variables of autonomic nerve function in Type 2 diabetes. ( Pop, A; Stirban, A; Tschoepe, D, 2013)
"Patients with type 2 diabetes and urinary albumin excretion in the high-normal and microalbuminuric range (15-300 mg/24h) were randomized to receive benfotiamine (n = 39) or placebo (n = 43)."2.77Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy. ( Alkhalaf, A; Bakker, SJ; Bilo, HJ; Gans, RO; Groenier, KH; Heeringa, P; Kleefstra, N; Navis, GJ; Schalkwijk, CG; Scheijen, JL, 2012)
"Patients with type 2 diabetes and UAE equivalent to 15-300 mg/24 h, despite ACE inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs), were randomly assigned to 12 weeks of benfotiamine (900 mg/day) (n = 39) or placebo (n = 43)."2.75A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. ( Achenbach, U; Alkhalaf, A; Bakker, SJ; Bilo, HJ; Gans, RO; Kleefstra, N; Klooster, A; Mijnhout, GS; Navis, GJ; Slingerland, RJ; van Oeveren, W, 2010)
"165 patients with symmetrical, distal diabetic polyneuropathy were randomised to one of three treatment groups entering the wash-out phase and 133/124 patients were analysed in the ITT/PP analysis: Benfotiamine 600 mg per day (n=47/43), benfotiamine 300 mg per day (n=45/42) or placebo (n=41/39)."2.73Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. ( Achenbach, U; Bretzel, RG; Federlin, K; Gaus, W; Stracke, H, 2008)
"Thirteen people with type 2 diabetes were given a heat-processed test meal with a high AGE content (HAGE; 15."2.72Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. ( Gawlowski, T; Götting, C; Horstmann, T; Kleesiek, K; Koschinsky, T; Mueller-Roesel, M; Negrean, M; Stirban, A; Stratmann, B; Tschoepe, D; Uribarri, J; Vlassara, H, 2006)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (7.14)18.2507
2000's6 (42.86)29.6817
2010's6 (42.86)24.3611
2020's1 (7.14)2.80

Authors

AuthorsStudies
Bönhof, GJ1
Sipola, G1
Strom, A1
Herder, C1
Strassburger, K1
Knebel, B1
Reule, C1
Wollmann, JC1
Icks, A1
Al-Hasani, H1
Roden, M1
Kuss, O1
Ziegler, D1
Stirban, A4
Pop, A2
Tschoepe, D4
Fischer, A1
Heckermann, S1
Sergienko, VA1
Segin, VB1
Samir, A1
Sergienko, AA1
Alkhalaf, A2
Klooster, A1
van Oeveren, W1
Achenbach, U2
Kleefstra, N2
Slingerland, RJ1
Mijnhout, GS1
Bilo, HJ2
Gans, RO2
Navis, GJ2
Bakker, SJ2
Groenier, KH1
Heeringa, P1
Scheijen, JL1
Schalkwijk, CG2
Engelen, L1
Stehouwer, CD1
Haupt, E1
Ledermann, H1
Köpcke, W1
Negrean, M2
Stratmann, B2
Gawlowski, T1
Horstmann, T1
Götting, C2
Kleesiek, K2
Mueller-Roesel, M1
Koschinsky, T1
Uribarri, J1
Vlassara, H1
Jermendy, G1
Salomon, J1
Stracke, H1
Gaus, W1
Federlin, K1
Bretzel, RG1
Sadekov, RA1
Danilov, AB1
Veĭn, AM1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy[NCT00565318]Phase 486 participants (Anticipated)Interventional2007-12-31Completed
Effects of a Chronical Treatment With Benfotiamine in People With Type 2 Diabetes Mellitus on Pre- and Postprandial Endothelial Function, as Well as on the Function of the Autonomic Nervous System[NCT00446810]Phase 430 participants (Anticipated)Interventional2007-09-30Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for benphothiamine and Diabetes Mellitus, Adult-Onset

ArticleYear
Current therapeutic interventions in the glycation pathway: evidence from clinical studies.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:8

    Topics: Animals; Atherosclerosis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathie

2013

Trials

9 trials available for benphothiamine and Diabetes Mellitus, Adult-Onset

ArticleYear
BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy.
    BMJ open, 2022, Feb-03, Volume: 12, Issue:2

    Topics: Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Humans; Polyneuropathies; Qua

2022
A randomized, double-blind, crossover, placebo-controlled trial of 6 weeks benfotiamine treatment on postprandial vascular function and variables of autonomic nerve function in Type 2 diabetes.
    Diabetic medicine : a journal of the British Diabetic Association, 2013, Volume: 30, Issue:10

    Topics: Adult; Aged; Antioxidants; Autonomic Pathways; Biomarkers; Blood Glucose; Cross-Over Studies; Diabet

2013
Variability of skin autofluorescence measurement over 6 and 12 weeks and the influence of benfotiamine treatment.
    Diabetes technology & therapeutics, 2013, Volume: 15, Issue:9

    Topics: Adult; Aged; Chelating Agents; Cross-Over Studies; Diabetes Complications; Diabetes Mellitus, Type 2

2013
A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy.
    Diabetes care, 2010, Volume: 33, Issue:7

    Topics: Adjuvants, Immunologic; Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotens

2010
Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy.
    PloS one, 2012, Volume: 7, Issue:7

    Topics: Aged; Biomarkers; Cell Adhesion Molecules; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endoth

2012
Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study).
    International journal of clinical pharmacology and therapeutics, 2005, Volume: 43, Issue:2

    Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type

2005
Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes.
    Diabetes care, 2006, Volume: 29, Issue:9

    Topics: Adjuvants, Immunologic; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; En

2006
Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study.
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2008, Volume: 116, Issue:10

    Topics: Adjuvants, Immunologic; Adult; Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic

2008
[Diabetic polyneuropathy treatment by milgamma-100 preparation].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 1998, Volume: 98, Issue:9

    Topics: Adult; Chelating Agents; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Drug Therapy, Combination

1998

Other Studies

4 other studies available for benphothiamine and Diabetes Mellitus, Adult-Onset

ArticleYear
[The effect of long-chain polyunsaturated higher ω-3 fatty acids, benfotiamine and α-lipoic acid on the lipid metabolism in patients with diabetes mellitus type 2 and cardiovascular autonomic neuropathy].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2013, Volume: 113, Issue:11

    Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; D

2013
[Oral benfotiamine therapy. Thus you protect the nerves of diabetic patients].
    MMW Fortschritte der Medizin, 2004, Jan-29, Volume: 146, Issue:5

    Topics: Administration, Oral; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Melli

2004
Evaluating thiamine deficiency in patients with diabetes.
    Diabetes & vascular disease research, 2006, Volume: 3, Issue:2

    Topics: Case-Control Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Male; Mi

2006
Adiponectin decreases postprandially following a heat-processed meal in individuals with type 2 diabetes: an effect prevented by benfotiamine and cooking method.
    Diabetes care, 2007, Volume: 30, Issue:10

    Topics: Adiponectin; Analysis of Variance; Body Mass Index; Chelating Agents; Cooking; Diabetes Mellitus, Ty

2007